These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 32067585)

  • 21. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
    Pollock RF; Muduma G
    J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
    [No Abstract]   [Full Text] [Related]  

  • 23. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
    Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
    Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
    Ponikowski P; Filippatos G; Colet JC; Willenheimer R; Dickstein K; Lüscher T; Gaudesius G; von Eisenhart Rothe B; Mori C; Greenlaw N; Ford I; Macdougall I; Anker SD;
    Eur J Heart Fail; 2015 Mar; 17(3):329-39. PubMed ID: 25683972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.
    Filippatos G; Farmakis D; Colet JC; Dickstein K; Lüscher TF; Willenheimer R; Parissis J; Gaudesius G; Mori C; von Eisenhart Rothe B; Greenlaw N; Ford I; Ponikowski P; Anker SD
    Eur J Heart Fail; 2013 Nov; 15(11):1267-76. PubMed ID: 23787722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in left atrial strain following ferric carboxymaltose in heart failure: an analysis of the Myocardial-IRON trial.
    Santas E; Del Canto I; Cardells I; Miñana G; Llàcer P; Almenar L; Fácila L; Maceira AM; Sanchis J; Núñez J;
    ESC Heart Fail; 2024 Apr; 11(2):1258-1262. PubMed ID: 38115745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.
    Anker SD; Colet JC; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Mori C; von Eisenhart Rothe B; Pocock S; Poole-Wilson PA; Ponikowski P;
    Eur J Heart Fail; 2009 Nov; 11(11):1084-91. PubMed ID: 19875408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial.
    Spahn DR; Schoenrath F; Spahn GH; Seifert B; Stein P; Theusinger OM; Kaserer A; Hegemann I; Hofmann A; Maisano F; Falk V
    Lancet; 2019 Jun; 393(10187):2201-2212. PubMed ID: 31036337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
    Lee S; Ryu KJ; Lee ES; Lee KH; Lee JJ; Kim T
    J Obstet Gynaecol Res; 2019 Apr; 45(4):858-864. PubMed ID: 30932300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction.
    Drozd MD; Tkaczyszyn M; Kasztura M; Węgrzynowska-Teodorczyk K; Flinta I; Banasiak W; Ponikowski P; Jankowska EA
    Cardiol J; 2024; 31(2):300-308. PubMed ID: 37853824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD - the exploratory randomized controlled double-blind ExplorIRON-CKD study.
    Kassianides X; Bhandari S
    BMC Nephrol; 2024 Feb; 25(1):54. PubMed ID: 38347520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
    Pollock RF; Muduma G
    Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Meta-analysis of Intravenous Iron Therapy for Patients With Iron Deficiency and Heart Failure.
    Osman M; Syed M; Balla S; Kheiri B; Faisaluddin M; Bianco C
    Am J Cardiol; 2021 Feb; 141():152-153. PubMed ID: 33259800
    [No Abstract]   [Full Text] [Related]  

  • 36. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
    Mahey R; Kriplani A; Mogili KD; Bhatla N; Kachhawa G; Saxena R
    Int J Gynaecol Obstet; 2016 Apr; 133(1):43-8. PubMed ID: 26868063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.
    Roger SD; Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Cronin M; Meier Y; Larroque S; Macdougall IC;
    Nephrol Dial Transplant; 2017 Sep; 32(9):1530-1539. PubMed ID: 28339831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Bailie GR; Mason NA; Valaoras TG
    Hemodial Int; 2010 Jan; 14(1):47-54. PubMed ID: 19888949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
    Okonko DO; Grzeslo A; Witkowski T; Mandal AK; Slater RM; Roughton M; Foldes G; Thum T; Majda J; Banasiak W; Missouris CG; Poole-Wilson PA; Anker SD; Ponikowski P
    J Am Coll Cardiol; 2008 Jan; 51(2):103-12. PubMed ID: 18191732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.